Variable | TXA group N = 289 | Control group N = 320 | P |
---|---|---|---|
Age, yr | 84.41 ± 7.38 | 85.21 ± 8.27 | 0.210 |
Gender, F/M | 198/91 | 214/106 | 0.666 |
Height, cm | 162.72 ± 9.49 | 162.47 ± 7.65 | 0.724 |
Weight, kg | 60.82 ± 12.90 | 58.60 ± 12.02 | 0.058 |
BMI, kg/m2 | 24.12 ± 2.49 | 22.11 ± 3.85 | 0.155 |
Anesthesia, n (%) | |||
General | 129 (44.64) | 114 (35.63) | 0.057 |
CSE | 79 (27.34) | 110 (34.38) | |
Spine | 81 (28.03) | 96 (30) | |
ASA rating, n (%) | |||
I | 63 (21.80) | 86 (26.88) | 0.230 |
II | 116 (40.14) | 107 (33.44) | |
III | 109 (37.72) | 124 (38.75) | |
IV | 1 (0.34) | 3 (0.93) | |
Comorbidities, n (%) | |||
0 | 24 (8.30) | 47 (14.69) | 0.074 |
1 | 95 (32.87) | 90 (28.13) | |
2 | 112 (38.75) | 121 (37.81) | |
3 | 34 (11.76) | 44 (13.75) | |
≥ 4 | 24 (8.30) | 18 (5.63) | |
Pre Hb level | 123.02 ± 14.65 | 120.74 ± 15.94 | 0.068 |
Pre Hct level | 0.36 ± 0.04 | 0.35 ± 0.04 | 0.057 |
Anticoagulation therapy, n (%) | |||
Rivaroxaban | 92 (31.83) | 79 (24.69) | 0.106 |
LMWH | 181 (62.63) | 216 (67.5) | |
None | 16 (5.54) | 25 (7.81) | |
Timing of initiation of VTE prophylaxis, n (%) | |||
Pre | 159 (55.02) | 180 (56.25) | 0.068 |
≤ 12 h Post | 105 (36.33) | 94 (29.38) | |
> 12 h Post | 9 (3.11) | 21 (6.56) | |
None | 16 (5.54) | 25 (7.81) | |
Pre ESA | 156 (53.98) | 183 (57.19) | 0.426 |
Cementless/Cement, n/n | 200/89 | 220/100 | 0.904 |
Operation time, min | 88.19 ± 31.55 | 92.35 ± 49.16 | 0.220 |
Intra-Crystalloid, ml | 785.12 ± 117.83 | 1063.42 ± 063.4 | 0.329 |
Intra-Colloid, ml | 221.86 ± 195.85 | 312.00 ± 230.66 | 0.277 |
PBV, ml | 3849.19 ± 639.74 | 37,771.80 ± 652.23 | 0.141 |
Hospital level | |||
<1000 procedures/year | 108 (37.37) | 109 (34.06) | 0.693 |
1000–2000 | 109 (37.72) | 128 (40.00) | |
>2000 | 72 (24.91) | 83 25.94() | |
Surgeon level | |||
<200 procedures/ year | 75 (25.95) | 104 (32.50) | 0.197 |
200–300 | 188 (65.05) | 192 (60.00) | |
>300 | 26 (9.00) | 24 (7.50) |